

10/507,361

=> file caplus  
FILE 'CAPLUS' ENTERED AT 11:43:23 ON 16 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 16 Feb 2006 VOL 144 ISS 8  
FILE LAST UPDATED: 15 Feb 2006 (20060215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 83 SEA FILE=REGISTRY SSS FUL L1

L4 2 SEA FILE=CAPLUS L3

=> d l4 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:740605 CAPLUS  
DOCUMENT NUMBER: 141:260752  
TITLE: Preparation of tetracyclic sulfenamide compounds as for the treatment of digestive ulcers  
INVENTOR(S): Nagasawa, Masaaki; Asami, Kazuyasu; Furuta, Shigeru; Miura, Naoyoshi; Morita, Hitoshi  
PATENT ASSIGNEE(S): Zeria Pharmaceutical Co. Ltd., Japan  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

WO 2004077367 A1 20040910 WO 2004-JP2107 20040224  
 W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,  
 BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,  
 CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,  
 ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,  
 IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,  
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,  
 MZ, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2003-46736 A 20030225  
 OTHER SOURCE(S): MARPAT 141:260752  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = (un)substituted alkyl with hydroxy, alkoxy carbonyl, etc.; R2, R4 = H, alkyl, alkoxy; R3 = (un)substituted alkoxy with halo, etc., further details on R3; A = benzene, pyridine, thiophene ring; B = single bond, etc.; Z = counter anion] were prepared. For example, exposure of compound II Na salt to tetrafluoroboric acid in ethanol afforded compound III. In H<sup>+</sup>/K<sup>+</sup> ATPase inhibition assays, the IC<sub>50</sub> value of compound III was 1.28 μM. Compds. I are claimed useful as therapeutic agent for digestive ulcers.


IT 611207-37-5 611207-40-0 611207-64-8

611207-76-2 611207-77-3 756486-74-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of tetracyclic sulfenamide compds. as for the treatment of digestive ulcers)


RN 611207-37-5 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-40-0 CAPLUS


CN 1H-Benzimidazol-1-amine, N-(2-methylpropyl)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



10/507,361


RN 611207-64-8 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3-methoxy-4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-76-2 CAPLUS

CN Ethanol, 2-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611207-77-3 CAPLUS

CN 1H-Benzimidazol-1-amine, N-methyl-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 756486-74-5 CAPLUS

CN 1H-Benzimidazolol, 1-amino-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



D1-OH

REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS


## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:796690 CAPLUS  
 DOCUMENT NUMBER: 139:307761  
 TITLE: Preparation of 1-N-aminobenzimidazole derivatives as proton pump inhibitors  
 INVENTOR(S): Nagasawa, Masaaki; Nishioka, Hiroyasu; Asami, Kazuyasu; Miura, Naoyoshi; Nakamura, Hideki; Morita, Hitoshi  
 PATENT ASSIGNEE(S): Zeria Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082854	A1	20031009	WO 2003-JP3996	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480890	AA	20031009	CA 2003-2480890	20030328
AU 2003220960	A1	20031013	AU 2003-220960	20030328
EP 1491539	A1	20041229	EP 2003-715613	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005148634	A1	20050707	US 2003-507361	20030328
PRIORITY APPLN. INFO.:			JP 2002-96143	A 20020329
			WO 2003-JP3996	W 20030328

OTHER SOURCE(S): MARPAT 139:307761

GI



AB The title compds. I [A1 represents (O)n; R1 and R2 represent each optionally substituted alkyl, etc.; R3, R5 and R6 represent each alkyl, alkoxy, hydrogen, etc.; R4 represents optionally substituted alkyl, etc.; A represents a benzene ring, etc.; B represents oxygen, etc.; and n is an integer of from 0 to 2] are prepared Because of showing little individual

differences in the therapeutic effect based on individual differences in the CYP2C19 activity, the compds. I can exert an appropriate therapeutic effect on any patient in a single administration dose. Moreover, these compds. carry little risk of the interaction or carcinogenesis induced by CYP1A family members. Thus, they are useful as safe remedies for digestive ulcer. In an vitro test for proton pump inhibiting effects, compds. of this invention showed IC50 values of 0.87  $\mu\text{mol/L}$  to 5.85  $\mu\text{mol/L}$ .


IT 611207-37-5P 611207-38-6P 611207-39-7P  
 611207-40-0P 611207-41-1P 611207-42-2P  
 611207-43-3P 611207-44-4P 611207-45-5P  
 611207-46-6P 611207-47-7P 611207-48-8P  
 611207-49-9P 611207-50-2P 611207-51-3P  
 611207-52-4P 611207-53-5P 611207-54-6P  
 611207-55-7P 611207-56-8P 611207-57-9P  
 611207-58-0P 611207-59-1P 611207-60-4P  
 611207-61-5P 611207-62-6P 611207-63-7P  
 611207-64-8P 611207-65-9P 611207-66-0P  
 611207-67-1P 611207-68-2P 611207-69-3P  
 611207-70-6P 611207-71-7P 611207-72-8P  
 611207-73-9P 611207-74-0P 611207-75-1P  
 611207-76-2P 611207-77-3P 611207-78-4P  
 611207-79-5P 611207-80-8P 611207-81-9P  
 611207-82-0P 611207-83-1P 611207-84-2P  
 611207-85-3P 611207-86-4P 611207-87-5P  
 611207-88-6P 611207-89-7P 611207-90-0P  
 611207-91-1P 611207-92-2P 611207-93-3P  
 611207-94-4P 611207-95-5P 611207-96-6P  
 611207-97-7P 611207-98-8P 611207-99-9P  
 611208-00-5P 611208-01-6P 611208-02-7P  
 611208-03-8P 611208-04-9P 611208-05-0P  
 611208-06-1P 611208-07-2P 611208-08-3P  
 611208-09-4P 611208-10-7P 611208-11-8P  
 611208-12-9P 611208-13-0P 611208-14-1P  
 611208-15-2P 611208-16-3P 611208-17-4P  
 611208-18-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-N-aminobenzimidazole derivs. as proton pump inhibitors)

RN 611207-37-5 CAPPLUS


CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-38-6 CAPPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 611207-39-7 CAPLUS


CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 611207-40-0 CAPLUS

CN 1H-Benzimidazol-1-amine, N-(2-methylpropyl)-2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-41-1 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[4-methoxy-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-42-2 CAPLUS


CN 1H-Benzimidazol-1-amine, 2-[[4-methoxy-5-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-43-3 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[5-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-44-4 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-45-5 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[(4-methoxy-6-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-46-6 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[6-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)


10/507,361




RN 611207-47-7 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[(4-methoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-48-8 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-49-9 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[(4-ethoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-50-2 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[(3-methyl-4-propoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-51-3 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(1-methylethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-52-4 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[4-butoxy-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-53-5 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(2-methylpropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-54-6 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[4-(hexyloxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-55-7 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(octyloxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-56-8 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-57-9 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-58-0 CAPLUS


CN 1H-Benzimidazol-1-amine, 2-[[[4-[(3,7-dimethyl-2,6-octadienyl)oxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-59-1 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-60-4 CAPLUS  
 CN Ethanol, 2-[[2-[[1-amino-1H-benzimidazol-2-yl)sulfinyl]methyl]-3-methyl-4-pyridinyl]oxy]- (9CI) (CA INDEX NAME)




RN 611207-61-5 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-62-6 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[[3-methoxy-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-63-7 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-64-8 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[3-methoxy-4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-65-9 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-66-0 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-67-1 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[5-methyl-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-68-2 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[5-methyl-4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-69-3 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[3,5-dimethyl-4-(4,4,4-trifluorobutoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-70-6 CAPLUS  
CN 1H-Benzimidazol-1-amine, 2-[[[3,5-dimethyl-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-71-7 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-72-8 CAPLUS  
 CN Acetamide, N-[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 611207-73-9 CAPLUS  
 CN Propanamide, 2,2-dimethyl-N-[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 611207-74-0 CAPLUS  
 CN 1-Propanol, 3-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 611207-75-1 CAPLUS


CN 1-Propanol, 3-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 611207-76-2 CAPLUS

CN Ethanol, 2-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)



RN 611207-77-3 CAPLUS


CN 1H-Benzimidazol-1-amine, N-methyl-2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



10/507,361


RN 611207-78-4 CAPLUS

CN 1H-Benzimidazol-1-amine, N-ethyl-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-79-5 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 611207-80-8 CAPLUS

CN 1H-Benzimidazol-1-amine, N-(1-methylethyl)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-81-9 CAPLUS

CN 1H-Benzimidazol-1-amine, N-butyl-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-82-0 CAPLUS


CN 1H-Benzimidazol-1-amine, N-hexyl-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611207-83-1 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 611207-84-2 CAPLUS  
 CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 611207-85-3 CAPLUS  
 CN 1H-Benzimidazol-1-amine, N-(2-methoxyethyl)-2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 611207-86-4 CAPLUS  
 CN Glycine, N-[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 611207-87-5 CAPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-(2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl)-1H-benzimidazol-1-yl)- (9CI)  
(CA INDEX NAME)


RN 611207-88-6 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 611207-89-7 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 611207-90-0 CAPLUS

CN Benzenemethanol, alpha-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 611207-91-1 CAPLUS

CN Phenol, 4-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 611207-92-2 CAPLUS

CN 1-Butanol, 4-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611207-93-3 CAPLUS


CN 1-Pentanol, 5-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)



RN 611207-94-4 CAPLUS  
 CN 2-Propanol, 1-[[2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611207-95-5 CAPLUS  
 CN 1-Propanol, 3-[[2-[[3,4-dimethoxy-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)



RN 611207-96-6 CAPLUS  
 CN 1-Propanol, 3-[[2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 611207-97-7 CAPLUS  
 CN 1-Propanol, 3-[[2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]-, (-)- (9CI) (CA INDEX NAME)

10/507,361


INDEX NAME)

Rotation (-).




RN 611207-98-8 CAPLUS

CN 1-Propanol, 3-[2-[[4-(2-methoxyethoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-ylamino]- (9CI) (CA INDEX NAME)




RN 611207-99-9 CAPLUS

CN 1-Propanol, 3-[2-[[3-methoxy-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-ylamino]- (9CI) (CA INDEX NAME)



RN 611208-00-5 CAPLUS


CN 1-Propanol, 3-[2-[[3-methoxy-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-ylamino]- (9CI) (CA INDEX NAME)



10/507,361


RN 611208-01-6 CAPLUS

CN 1-Propanol, 3-[[2-[[3-methoxy-4-[2-(2,2,2-trifluoroethoxy)ethoxy]-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611208-02-7 CAPLUS

CN 1-Propanol, 3-[[2-[[3-methyl-4-[3-(2,2,2-trifluoroethoxy)propoxy]-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611208-03-8 CAPLUS

CN 2-Propanol, 1-[[2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611208-04-9 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 611208-05-0 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-amino-2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl- (9CI) (CA INDEX NAME)




RN 611208-06-1 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-amino-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611208-07-2 CAPLUS

CN 1H-Benzimidazole-5-carbonitrile, 1-amino-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611208-08-3 CAPLUS

CN 1H-Benzimidazole-5-acetic acid, 1-amino-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 611208-09-4 CAPLUS

CN 1H-Benzimidazol-1-amine, 6-(fluoromethoxy)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611208-10-7 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3,5-dimethyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 611208-11-8 CAPLUS

CN 1H-Benzimidazol-1-amine, 2-[[[3,5-dimethyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 611208-12-9 CAPLUS

CN 1H-Benzimidazol-1-amine, 5-(fluoromethoxy)-2-[[[3-methoxy-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611208-13-0 CAPLUS


CN 1H-Benzimidazol-1-amine, 6-(fluoromethoxy)-2-[[[3-methoxy-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 611208-14-1 CAPLUS  
 CN 1-Propanol, 3-[[5-(fluoromethoxy)-2-[[3-methoxy-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)



RN 611208-15-2 CAPLUS  
 CN 1-Propanol, 3-[[6-(fluoromethoxy)-2-[[3-methoxy-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-1-yl]amino]- (9CI) (CA INDEX NAME)




RN 611208-16-3 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 1-[(3-hydroxypropyl)amino]-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 611208-17-4 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 1-[(3-hydroxypropyl)amino]-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

10/507,361



RN 611208-18-5 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 1-[(3-hydroxypropyl)amino]-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall


FILE 'USPATFULL' ENTERED AT 11:44:15 ON 16 FEB 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:44:15 ON 16 FEB 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 83 SEA FILE=REGISTRY SSS FUL L1

L5 1 SEA L3

=> d 15 ibib abs hit

L5 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2005:171885 USPATFULL

TITLE: 1-N-Aminobenzimidazole derivatives

INVENTOR(S): Nagasawa, Masaaki, Osato-Gun, JAPAN

Nishioka, Hiroyasu, Osato-Gun, JAPAN

Asami, Kazuyasu, Osato-Gun, JAPAN

10/507,361

Miura, Naoyoshi, Osato-Gun, JAPAN  
Nakamura, Hideki, Osato-Gun, JAPAN  
Morita, Hitoshi, Osato-Gun, JAPAN  
**PATENT ASSIGNEE(S):** ZERIA PHARMACEUTICAL CO., LTD, Tokyo, JAPAN, 103-8351  
(non-U.S. corporation)

	NUMBER	KIND	DATE
<b>PATENT INFORMATION:</b>	US 2005148634	A1	20050707
<b>APPLICATION INFO.:</b>	US 2003-507361	A1	20030328 (10)
	WO 2003-JP3996		20030328

	NUMBER	DATE
<b>PRIORITY INFORMATION:</b>	JP 2003-2002096143	20020329
<b>DOCUMENT TYPE:</b>	Utility	
<b>FILE SEGMENT:</b>	APPLICATION	
<b>LEGAL REPRESENTATIVE:</b>	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US	
<b>NUMBER OF CLAIMS:</b>	10	
<b>EXEMPLARY CLAIM:</b>	1	
<b>LINE COUNT:</b>	2608	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

**AB** Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I): ##STR1## wherein R.<sup>1</sup> and R.<sup>2</sup> each represents a substituted or unsubstituted alkyl group or the like, R.<sup>3</sup>, R.<sup>5</sup> and R.<sup>6</sup> each represents an alkyl group, alkoxy group, hydrogen atom or the like, R.<sup>4</sup> represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them. The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family. Accordingly, they are useful as peptic ulcer therapeutic agents which are safe and surely bring about therapeutic effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

**IT** 611207-37-5P 611207-38-6P 611207-39-7P  
611207-40-0P 611207-41-1P 611207-42-2P  
611207-43-3P 611207-44-4P 611207-45-5P  
611207-46-6P 611207-47-7P 611207-48-8P  
611207-49-9P 611207-50-2P 611207-51-3P  
611207-52-4P 611207-53-5P 611207-54-6P  
611207-55-7P 611207-56-8P 611207-57-9P  
611207-58-0P 611207-59-1P 611207-60-4P  
611207-61-5P 611207-62-6P 611207-63-7P  
611207-64-8P 611207-65-9P 611207-66-0P  
611207-67-1P 611207-68-2P 611207-69-3P  
611207-70-6P 611207-71-7P 611207-72-8P  
611207-73-9P 611207-74-0P 611207-75-1P  
611207-76-2P 611207-77-3P 611207-78-4P  
611207-79-5P 611207-80-8P 611207-81-9P  
611207-82-0P 611207-83-1P 611207-84-2P  
611207-85-3P 611207-86-4P 611207-87-5P  
611207-88-6P 611207-89-7P 611207-90-0P  
611207-91-1P 611207-92-2P 611207-93-3P  
611207-94-4P 611207-95-5P 611207-96-6P  
611207-97-7P 611207-98-8P 611207-99-9P

10/507,361

611208-00-5P 611208-01-6P 611208-02-7P  
611208-03-8P 611208-04-9P 611208-05-0P  
611208-06-1P 611208-07-2P 611208-08-3P  
611208-09-4P 611208-10-7P 611208-11-8P  
611208-12-9P 611208-13-0P 611208-14-1P  
611208-15-2P 611208-16-3P 611208-17-4P  
611208-18-5P 611208-19-6P 611208-20-9P 611208-21-0P  
611208-22-1P 611208-23-2P 611208-24-3P  
(preparation of 1-N-aminobenzimidazole derivs. as proton pump inhibitors)

=>